There’s no understating the impact that delayed or denied claims can have on your organization’s bottom line – particularly claims in which clinicians at hospitals and health systems administer medication as part of the treatment plan.
In this month’s 340Buzz, we’ll look at a flurry of legislative activities related to 340B: bills introduced, letters proffered, new rules for alternative dispute resolution, most-favored-nation pricing and Medicare Part D rebates. We’ll also share some of the buzz on who may be joining the new administration in key health policy roles.
Sentry Data Systems is proud to announce that its Sentinel platform now features fully seamless integration with each of the so-called ‘Big Three’ drug wholesalers: McKesson, AmerisourceBergen and Cardinal Health.
By the time you read this, much will have changed. A new Supreme Court Justice has been confirmed, shifting the political balance of the court. A presidential election will transpire shortly, with its many implications for the Affordable Care Act, the 340B program, drug pricing, Medicaid and Medicare – no matter who wins. While we wait for change, we’ll take a closer look at some important October events – from continued actions by manufacturers, congressional actions and the potential impact of the Supreme Court.
Safety net healthcare providers are under enormous pressure on multiple fronts these days. The 340B Drug Pricing Program is under assault from drug manufacturers, CMS’s proposed 340B reimbursement cuts are tied up in the courts and the COVID-19 pandemic is putting the squeeze on finances and staffing levels. With all the chaos and uncertainty, it’s especially important for covered entities to capture as much savings as possible to optimize their 340B program.
It’s important to understand that capturing referrals for eligible patients is 100% compliant with 340B regulations. So don’t let the complexities of managing referral provider relationships prevent you from realizing additional 340B benefit.
Learn how to maximize your 340B benefits and make the program work for you. The next round of our Foundations Certificate training program begins in November.
A deeper dive into strategies pharmaceutical companies have been cooking up to curtail the 340B program and skirt payment requirements.
In response to the COVID-19 pandemic, HRSA’s Office of Pharmacy Affairs has made a number of adjustments to its guidelines for the 340B drug pricing program for stakeholders.
We take a deeper dive into the moves pharma has been making and the executive order affecting FQHCs that we mentioned in previous blogs last month, discuss the long-awaited court decision about the Medicare part B reimbursement cuts, and we also take a look at HRSA’s new registration and recertification requirements.